Rutin
| 證據等級: L5 | 預測適應症: 8 個 |
目錄
Rutin: From Undocumented Original Indication to Breast Fibrocystic Disease
One-Sentence Summary
Rutin (DrugBank ID DB01698) is a flavonoid glycoside; no original indication or marketing license record is available in this evidence pack, and it is currently not marketed in the covered jurisdiction. The TxGNN model predicts potential efficacy for Breast Fibrocystic Disease (score 99.74%), but this prediction is currently supported by zero clinical trials and zero publications — it rests entirely on the model’s statistical score.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no license or indication records in evidence pack) |
| Predicted New Indication | Breast Fibrocystic Disease |
| TxGNN Prediction Score | 99.74% |
| Evidence Level | L5 (model prediction only) |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for Rutin is not available (flagged as a High-severity data gap in this evidence pack). Based on general pharmacological knowledge, Rutin is a flavonoid glycoside (quercetin-3-rutinoside) with reported antioxidant, anti-inflammatory, and microvascular-stabilizing properties. The evidence pack’s own rationale suggests these properties could theoretically reduce local inflammation and oxidative stress relevant to benign proliferative breast lesions — but this is explicitly characterized as pharmacological inference, not a mechanism established by direct study of Rutin in this indication.
No original indication is documented for Rutin in this evidence pack, so no relationship between an established use and the predicted new indication can be drawn. Combined with the complete absence of clinical trials or literature specific to Rutin in breast fibrocystic disease, this prediction should be treated as a hypothesis generated purely by the TxGNN model, not as a mechanistically or clinically substantiated candidate.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
No marketing authorization records are currently available — Rutin is not marketed in the covered jurisdiction (0 licenses on file).
Safety Considerations
Please refer to the package insert for safety information. (Key warnings, contraindications, and drug interaction data are currently unavailable in this evidence pack.)
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for Rutin in breast fibrocystic disease is Evidence Level L5 — a model score with no clinical trials, no supporting literature, no documented mechanism of action, and no marketing history in the target jurisdiction. There is currently no basis to advance beyond hypothesis generation.
To proceed, the following is needed:
- Confirmed mechanism of action data (DrugBank API query — DG002, High severity)
- Package insert warnings/contraindications, once Rutin obtains any regulatory filing (DG001, Blocking severity)
- Documentation of Rutin’s actual original/traditional indication(s) for comparison
- At minimum, preclinical or mechanistic studies directly linking Rutin to breast fibrocystic disease before any clinical evidence search is prioritized
- Re-evaluation of whether this candidate merits further evidence-collection effort given its L5 status and absence of any market presence
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.